Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 140 mg hard capsules, Temodal 180 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NOX-A12, Temodal 250 mg hard capsules, MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Temodal 20 mg hard capsules, Temodal 250 mg hard capsules, Temodal 180
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
Tevimbra 100 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
1 trial -
Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione
Fondazione Telethon ETS
stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
Hoffmann-La Roche
Squamous cell carcinoma of the head and neck (SCCHN)
1 trial -
Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
Disc Medicine
HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor
1 trial -
Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669
Hoffmann-La Roche
Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
1 trial -
TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
1 trial -
TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
1 trial -
Trecondi 1 g powder for solution for infusion, FLUDARABINE PHOSPHATE, THIOTEPA, Trecondi 5 g powder for solution for infusion
Pari Pharma GmbH
Myelofibrosis
1 trial -
Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab
AstraZeneca AB
unresectable pleural or peritoneal malignant mesothelioma
1 trial -
Trimeton 10 mg/1 ml soluzione iniettabile, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Gazyvaro 1,000 mg concentrate for solution for infusion., TACHIPIRINA 500 mg compresse, MEDROL 16 mg compresse, CORTRIUM 40 mg/2 ml polvere e solvente per soluzione iniettabile
Istituto Gentili S.r.l.
Primary Membranous Nephropathy
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Gilead Sciences Pty Limited
Non-small cell lung cancer
1 trial -
Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®
The George Institute
Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.
1 trial -
Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab
Lacuna Pharma Pty Ltd
Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer
1 trial -
Ultomiris 300 mg/30 mL concentrate for solution for infusion, Concentrate for solution for infusion
Alexion Europe SAS
Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
1 trial -
Umbilical Cord Blood Infusion
Hospital Authority, Hong Kong
Cerebral Palsy
1 trial -
Uplizna 100 mg concentrate for solution for infusion
Amgen
Generalized Myasthenia Gravis
1 trial -
Uplizna 100 mg concentrate for solution for infusion
Amgen
Immunoglobulin G4 related Disease (IgG4-RD)
1 trial -
VAY736, Placebo Solution for injection or infusion 0 mg/1 mL
Novartis Pharmaceuticals
Moderate to severe hidradenitis suppurativa
1 trial -
VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)
Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
VINCRISTINE , MELPHALAN , DOXORUBICIN , CYCLOPHOSPHAMIDE , IFOSFAMIDE , Trecondi 1 g powder for solution for infusion, ETOPOSIDE , Trecondi 5 g powder for solution for infusion
Fondazione Telethon ETS
Ewing Sarcoma
1 trial -
VX-670 Solution for Injection/Infusion
Vertex Pharmaceuticals (Australia) Pty.
Myotonic Dystrophy
1 trial -
VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v)
Vertex Pharmaceuticals (Australia) Pty.
Myotonic Dystrophy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources